About this event
What if electronic Clinical Outcome Assessments (eCOA) could elevate your next rare disease trial?
Interview with Prof. Olivier Blin, Professor of Pharmacology, rare disease expert, and Orphan Dev coordinator
Despite remarkable progress in rare disease research, 90% of rare diseases still lack an approved treatment. This reality underscores the urgent need for continued innovation, patient advocacy, and smarter clinical trial designs.
What if eCOA could transform your next rare disease trial?
Imagine achieving higher data quality, stronger clinical relevance, and greater regulatory confidence.
Join us for this webinar where Prof. Olivier Blin will share:
- How eCOAs can help overcome key challenges in rare disease clinical trials
- Real-world examples of robust eCOA strategies delivering tangible value.
- How these approaches have streamlined regulatory processes and improved trial outcomes.
Don’t miss this opportunity to explore innovative solutions that can elevate your research!
Hosted by
-
Team member
Estelle HaenelT
Joined Kayentis as Chief Medical Officer in 2019. Estelle drives the scientific strategy of the company, collaborating with the scientific advisory board and focusing on patient and site engagement. She has 25+ years of experience in pre-clinical and clinical research in Top 5 Pharma and Biotech companies. A Doctor of Pharmacy, Estelle also has a Masters in Endocrinology and Cellular Interaction and a PhD in Biochemistry and Molecular Biology.
-
Guest speaker
Olivier Blin Professor of Pharmacology, rare disease expert, and Orphan Dev coordinatorG
Olivier BLIN (MD, PhD, MBA), is Professor of Pharmacology at Aix-Marseille University, certified in Neurology, Psychiatry and Medical Biology. He is one of the co-founders of Thelonius Mind, a consulting company specializing in drug development for rare and neurodegenerative diseases. At the national level, he is the coordinator of ORPHANDEV, the French National Network for Rare Diseases, labelled by F-CRIN. Former Head of the Clinical Pharmacology & Pharmacovigilance Department, Marseille University Hospital, member of the research unit UMR AMU-INSERM 1106, and coordinator of the University Hospital Federation DHUNE, COEN center on neurodegenerative disorders and aging (www.dhune.org), he is currently on sabbatical leave to be a Board Member of a clinical stage biotech, Tafalgie, spin-off of Aix-Marseille University and CNRS.
Kayentis
Embark on a seamless eCOA clinical trial experienceKayentis, a global leader in eCOA and Decentralized Clinical Trial solutions, empowers pharma, biotech, and CROs to streamline data collection in clinical trials, enhancing simplicity, efficiency, and data quality.
